NO984233L - Cytokin kalt lerk-8 - Google Patents

Cytokin kalt lerk-8

Info

Publication number
NO984233L
NO984233L NO984233A NO984233A NO984233L NO 984233 L NO984233 L NO 984233L NO 984233 A NO984233 A NO 984233A NO 984233 A NO984233 A NO 984233A NO 984233 L NO984233 L NO 984233L
Authority
NO
Norway
Prior art keywords
lerk
larch
cytokine called
called
cytokine
Prior art date
Application number
NO984233A
Other languages
English (en)
Other versions
NO984233D0 (no
Inventor
Douglas P Cerretti
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO984233D0 publication Critical patent/NO984233D0/no
Publication of NO984233L publication Critical patent/NO984233L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Oppfinnelsen er rettet mot et protein kalt Lerk-8, DNA som koder for Lerk-8, og vertsceller transformert med Lerk-8-DNA. Antistoffer som er immunreaktive med Lerk-8 er også tilveiebragt. Lerk-8-proteinet binder til celleoverflatereseptorene kjent som elk og hek.
NO984233A 1996-03-21 1998-09-14 Cytokin kalt lerk-8 NO984233L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62114696A 1996-03-21 1996-03-21
PCT/US1997/004533 WO1997036919A2 (en) 1996-03-21 1997-03-19 Cytokine designated lerk-8

Publications (2)

Publication Number Publication Date
NO984233D0 NO984233D0 (no) 1998-09-14
NO984233L true NO984233L (no) 1998-11-23

Family

ID=24488927

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984233A NO984233L (no) 1996-03-21 1998-09-14 Cytokin kalt lerk-8

Country Status (7)

Country Link
EP (1) EP0904287A3 (no)
JP (1) JP2001521368A (no)
KR (1) KR19990087793A (no)
AU (1) AU2538697A (no)
IL (1) IL125919A0 (no)
NO (1) NO984233L (no)
WO (1) WO1997036919A2 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004091A1 (en) * 1995-07-20 1997-02-06 Amrad Operations Pty. Ltd. Novel receptor ligands and genetic sequences encoding same
AU712737B2 (en) * 1995-10-25 1999-11-11 Regeneron Pharmaceuticals, Inc. Biologically active EPH family ligands
EP1553963A4 (en) 2002-09-24 2006-05-03 Burnham Inst NOVEL AGENTS MODULATING EPH RECEPTOR ACTIVITY
CN101146822A (zh) 2005-01-27 2008-03-19 伯纳姆研究所 EphB受体结合肽

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303769B1 (en) * 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
ATE346498T1 (de) * 1994-10-05 2006-12-15 Immunex Corp Als lerk6 bezeichnetes cytokin
ES2240981T3 (es) * 1994-12-06 2005-10-16 Immunex Corporation Citocina denominada lerk-7.

Also Published As

Publication number Publication date
WO1997036919A2 (en) 1997-10-09
KR19990087793A (ko) 1999-12-27
AU2538697A (en) 1997-10-22
EP0904287A2 (en) 1999-03-31
WO1997036919A3 (en) 2000-10-12
JP2001521368A (ja) 2001-11-06
NO984233D0 (no) 1998-09-14
EP0904287A3 (en) 2000-12-20
IL125919A0 (en) 1999-04-11

Similar Documents

Publication Publication Date Title
FI972390A (fi) Sytokiini nimeltä Lerk-7
NO965627D0 (no) Nytt cytokin betegnet lerk-5
ATE353906T1 (de) Cd27 ligand
FI960743A (fi) Sytokiineja, jotka sitoutuvat solun pinnan hekreseptoriin
DE68916423D1 (de) Enzymatisch verstärkter, piezoelektrischer, spezifischer bindungstest.
ES2075196T3 (es) Metodo para el uso y la sintesis de peptidos.
NO976045D0 (no) Cytokin som induserer apoptosis
DK0669929T3 (da) Elk-ligand, et cytokin
ATE341627T1 (de) Als lerk6 bezeichnetes cytokin
NO970740L (no) Glutamat reseptor
DE68928834D1 (de) Monoklonale antikörper gegen katzen-t-lymphotropes lentivirus
DE68917556D1 (de) Quinolyloxazol-2-one, nützlich als Proteinkinase-C-Inhibitoren.
NO882054L (no) Sementblanding, saerlig til bruk i borehull.
NO984233L (no) Cytokin kalt lerk-8
DE3485219D1 (de) Tgf-polypeptide, davon derivierte antigene oligopeptide, davon erhaltene antikoerper.
ES2178203T3 (es) Metodos y reactivos para modular la apoptosis.
DK43393D0 (da) Dna-sekvens, der koder for et enzym
BG103627A (en) New ifn receptor 1-binding proteins, dna encoding them, and methods for the modulation of a cellular response for interferons
BR0315222A (pt) Promotor de il-18bp, sua preparação e uso
DK459588D0 (da) Sorteringskonstruktion til jig
MX9701904A (es) Proteinas de enlace de pka novedosas y usos de las mismas.
IT8820298A0 (it) Dispositivo smorzatore per impalcati di viadotti, coperture esimili.
BRPI0216042B8 (pt) polipeptídeo capaz de se ligar a ang-2, vetor de expressão, célula hospedeira, composição farmacêutica, e, uso dos referidos polipeptídeos.
MX9700213A (es) Citocina novedosa designada como lerk-5.
ATE105291T1 (de) Spiro-isochinolin-pyrrolidin-tetrone und analoge davon, verwendbar als aldosereduktaseinhibitoren.